Due to policy boundaries, the results and conclusions of my thesis cannot be disclosed in this paper. Instead this paper will provide background information about myasthenia gravis (MG) and the role of immunoglobulin G (IgG) antibodies in autoimmune MG.
The neuromuscular junction
Motor units consist of motor neurons and groups of muscle fibers, which innervate the contraction of all muscles in our body. The neuromuscular junction (NMJ) is the synapse located between the motor neuron terminal and the muscle. The NMJ is responsible for the transmission of signals arriving from the central nervous system (CNS) to the muscles (figure 1) (1, 4) . The motor unit is frequently involved as a target for diseases whereby the cell body of a motor neuron, the axons of the motor neurons, the NMJ, or the muscles themselves are affected (1) . An altered or disrupted transmission of the neurotransmitters between the motor neuron and muscle cells characterize disorders of the NMJ.
Disorders of the NMJ can be divided into two categories. First, chemical transmission by neurotransmitters at the NMJ can be altered by defects in the presynaptic terminal.
The second form involves the postsynaptic membrane, also termed the motor endplate (1) . Several postsynaptic proteins are important for the functioning and maintenance of the NMJ, including the acetylcholine receptor (AChR), muscle specific kinase (MuSK), and low density lipoprotein receptor-related protein 4 (Lrp4). The AChR is responsible for signal transduction by binding the neurotransmitter acetylcholine (ACh). MuSK and Lrp4 are postsynaptic proteins essential in NMJ maintenance. The tyrosine kinase activity of MuSK plays a crucial role in an agrin-Lrp-MuSK signaling pathway that facilitates AChR clustering at the postsynaptic membrane. Hence, AChR clustering is necessary for signal transduction by depolarizing the muscle fibers after binding of ACh (figure 1) (4).
Myasthenia Gravis
MG, derived from fusing the Greek terms for muscle (mus) and weakness (sthenos) with the Latin term for severe (gravis) (5) , is a rare and often severe disorder of the NMJ and characterized by fatigable muscle weakness in skeletal muscles (6, 7) . The symptoms usually occur after use of affected muscles and ameliorate after rest (6) . Two major subsets of MG are currently recognized: congenital and autoimmune MG. Congenital MG is characterized by inherited defects in some components of the NMJ caused by mutations.
Autoimmune MG is the most prevalent form of MG (1). In patients with autoimmune MG, antibodies are produced against extracellular components of the NMJ (6) (7) (8) .
Approximately, 80-90% of MG patients have been diagnosed with AChR-MG affecting approximately 90 persons per million inhabitants in the Netherlands (9) . In about 20% of the MG patients no antibodies directed to AChR are detected. Antibodies to other important proteins than the AChR have been identified during the last decade.
Approximately, 50% of this group have been diagnosed with antibodies directed to MuSK, affecting approximately 1.9 persons per million inhabitants in the Netherlands (9) . More recently, antibodies to Lrp4 have been identified. Together, antibodies directed against these three proteins currently characterize the three most distinct forms of MG (8) .
Different clinical subtypes of MG have been described which can be distinguished from each other according to age of onset and topography of the altered NMJ transmission (6) .
In 67% of all MG patients, the ocular muscles are initially affected causing symptoms as diplopia and ptosis. In a small subgroup of patients, this can be the only manifestation of the disease. However, in other MG patients the symptoms can become more generalized.
The ocular symptoms are usually followed by affected bulbar and limb muscles (6) .
MG with anti-MuSK antibodies often involves fluctuating weakness of bulbar and respiratory muscles. When respiratory muscles are affected, the disease becomes more life threatening. During a crisis, the patients might require intensive care and mechanical ventilation (10) . Diagnosis of MG currently relies on serological and electrodiagnostic tests. Therapies currently in use include anti-cholinesterase drugs, immunosuppression, immunomodulation, and a novel drug named rituximab (6) .
It has been suggested that environmental and/or genetic factors play a role in the susceptibility to develop the disease. The prevalence of MuSK-MG differs in different geographic regions and ethnic groups. For example, the prevalence of MuSK-MG is low in Taiwan and Denmark, whereas it is high in North American, British and Italian populations (9, 11) . Furthermore, MuSK-MG has been associated with the human leukocyte antigen (HLA) DR14-DQ5 haplotypes (12) whereas AChR-MG has been associated with among others HLA-B8DR3 (8, 13) .
Antibodies and effector mechanisms in autoimmune myasthenia gravis
Autoimmune MG is an antibody-mediated autoimmune disorder fulfilling the Witebsky postulates, since (i) antibodies are present at the NMJ, (ii) immunoglobulins from MG patients cause MG symptoms in rodents, and (iii) therapies that remove antibodies decrease the severity of the MG symptoms (15) . Different mechanisms have been This mechanism leads to removal of AChRs and destruction of the muscle membrane morphology (6, 8, 16 (20, 22, 23) . However, a contribution of IgG1, IgG2, and IgG3 have also been previously described. These IgG subclass molecules are thought to affect the NMJ and reduce AChR clusters (23). 
Unique properties of IgG4 subclass molecules
IgG4 is a unique IgG subclass with unique biological properties and structure. First, IgG4
is not able to bind C1q and to fixate the complement system. Second, an interesting difference in the sequence of IgG1-3 and IgG4 is located in the hinge region (18, 19) . A consequence of this difference is the increased susceptibility for chemical reduction of the disulfide bonds at the hinge region allowing heavy chains with attached light chain (half-antibody) to separate from each other (18) . This distinctive feature is the basis of the 
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is believed to attribute IgG4 antibodies with anti-inflammatory activity. Because these bispecific antibodies are monovalent for a specific antigen, they are unable to form immune complexes with an antigen, a property that the other IgG subclasses (IgG1, IgG2, and IgG4) do possess (18, 19) .
igg4 antibody production in MuSK-MG and other IgG4 mediated diseases
IgG levels have been investigated in pemphigus patients, revealing increased levels of the IgG4 subclass exclusively (24, 25) . Increased IgG4 levels have also been found in other IgG4 mediated diseases (26) . In healthy individuals, IgG4 levels increase after repeated exposure to an antigen. Yet, little is known about the immunologic factors that underlie the production of antigen specific IgG4 molecules. Interactions between T-lymphocytes and B-lymphocytes are crucial for the production of antibodies with a high affinity for its antigen. Particular cytokines regulate class switch gene rearrangements and influence the immunoglobulin subtypes that are being produced. Different T helper (Th) cells secrete these cytokines (27, 28) . The result of activated B-lymphocyte exposure to a particular cytokine is differentiation of the B-lymphocytes into an antibody producing plasma cell (27) . Like IgG4, IgE production is regulated by the secretion of Th2 cytokines (e.g. IL-4 and IL-13). In contrast to these cytokines, IL-10, IL-12, and IL-21 shift the balance towards IgG4 production (29) (30) (31) . It has been hypothesized that chronic exposure to an allergen provides a strong stimulus that induces a switch to IgG4 under exposure of IL-4 in the germinal centers. Furthermore, B-lymphocytes that express IgE would not survive herein (32) . It also has been suggested that T-regulatory (Treg) cells may be involved in IgG4 production (44). IL-10 produced by these Treg cells are thought to suppress IgE production and induce allergen-specific IgG4 producing plasma cells (33) . Several studies investigated cytokine profiles and the involvement of Th cells in MuSK-MG (45, 46), but it remains controversial which Th cells subset (Th1, Th2 or Th17) are involved in the development of MG. However, recently it has been suggested that the Th1 and Th17 subsets play a role in MuSK-MG (34) . Moreover, a decreased B10-lymphocyte percentage has been found in MuSK-MG patients. It is suggested that the loss of B10-lymphocytes and B10 derived IL-10 is involved in creating a permissive environment for autoantibody production and Th1 and Th17 immune responses, due to loss of self-tolerance (35) . The role of T and B-lymphocytes in the pathogenesis have yet to be elucidated. Future studies are needed to elucidate how antigen specific IgG4 production is regulated and induced in MuSK-MG. 
